Search
Peer-Reviewed Publication
Yellow fever in the diagnostics laboratory review-article
Domingo, C., Charrel, R.N., Schmidt-Chanasit, J., Zeller, H., Reusken, C.
Publication
Communicable disease threats report, 13-19 May 2018, Week 20
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 13-19 May 2018 and includes updates on E.coli, seasonal influenza, dengue, hepatitis A, measles, rubella, yellow fever and Ebola.
News
Public Health Emergency of International Concern (PHEIC) declared for Zika and clusters of microcephaly and neurological disorders
ECDC welcomes the decision of the WHO Director-General to declare a PHEIC, in light of evidence possibly linking microcephaly cases to Zika virus infections.
Publication
Communicable disease threats report, 24-30 January 2016, week 4
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 24-30 January 2016 and includes updates on Zika virus, Ebola virus disease and MERS.
Publication
Rapid Risk Assessment: Zika virus disease epidemic: potential association with microcephaly and Guillain-Barré syndrome (first update)
This updated rapid risk assessment evaluates the risks associated with the evolving Zika virus epidemic currently affecting some countries in the Americas, including the risk for travellers to the affected areas and populations in the affected EU outermost regions.
News
Epidemiological update: Complications potentially linked to the Zika virus outbreak, Brazil and French Polynesia
On 18 April 2014, the Hellenic Centre for Disease Control and Prevention (KEELPNO) announced a laboratory confirmed case of MERS-CoV infection in a 69 year old male patient.
News
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in EuropeArchived
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.